Abbott has reported new data from its Volt CE Mark Study in individuals treated with PFA therapy using the Volt PFA System ...

Abbott Laboratories (NYSE:ABT) recently announced promising results from its AVEIR Conduction System Pacing study, showcasing its innovative leadless pacemaker technology. Over the last quarter, the ...

Abbott (NYSE: ABT) has announced new data from its Volt CE Mark Study that show strong safety and efficacy out to 12 months ...

Emerging pulsed field ablation systems had their moments in the spotlight at the annual meeting of the Heart Rhythm Society ...

M.D., chief medical officer of Abbott's electrophysiology business. About the Volt CE Mark Study Abbott's Volt CE Mark Study is a prospective, single-arm, non-randomized, multicenter study ...

The company joins Johnson & Johnson and Abbott as top medtech firms that expect an impact in the hundreds of millions of ...

Often seen as an option of last resort for ventricular tachycardia, new research suggests catheter ablation could have a ...

Led by Farapulse founder Steven Mickelsen, Field has developed a pulsed field ablation device to tackle the dangerous heart ...

Thanks to healthcare reform, the hurdles to securing reimbursement and technology add-on payments have risen. Boston will need to invest more in clinical studies to demonstrate superiority of outcomes ...

For medically refractory vasovagal syncope (VVS) and functional bradycardia, the feasibility of off-label catheter ...